Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur Jurczyszyn, Jorge J. Castillo, Irit Avivi, Jacek Czepiel, Julio Davila, Ravi Vij, Mark A. Fiala, Alessandro Gozzetti, Norbert Grząśko, Vibor Milunovic, Iwona Hus, Krzysztof Mądry, Anna Waszczuk-Gajda, Lidia Usnarska-Zubkiewicz, Jakub Dębski, Erden Atilla, Meral Beksac, Giuseppe Mele, Waldemar Sawicki, David JayabalanGrzegorz Charliński, Agoston Gyula Szabo, Roman Hajek, Michel Delforge, Agnieszka Kopacz, Dorotea Fantl, Anders Waage, Edvan Crusoe, Vania Hungria, Paul Richardson, Jacob Laubach, Thomas Guerrero-Garcia, Jieqi Liu, David H. Vesole

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10 9 /L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p =.0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2 2019


  • Autologous stem cell transplantation
  • proteasome inhibitors
  • secondary plasma cell leukemia


Dive into the research topics of 'Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients'. Together they form a unique fingerprint.

Cite this